JP2015505309A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505309A5
JP2015505309A5 JP2014549542A JP2014549542A JP2015505309A5 JP 2015505309 A5 JP2015505309 A5 JP 2015505309A5 JP 2014549542 A JP2014549542 A JP 2014549542A JP 2014549542 A JP2014549542 A JP 2014549542A JP 2015505309 A5 JP2015505309 A5 JP 2015505309A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence identity
acid sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014549542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505309A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/056006 external-priority patent/WO2013098589A1/en
Publication of JP2015505309A publication Critical patent/JP2015505309A/ja
Publication of JP2015505309A5 publication Critical patent/JP2015505309A5/ja
Pending legal-status Critical Current

Links

JP2014549542A 2011-12-29 2011-12-29 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ Pending JP2015505309A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056006 WO2013098589A1 (en) 2011-12-29 2011-12-29 Adjuvanted combinations of meningococcal factor h binding proteins

Publications (2)

Publication Number Publication Date
JP2015505309A JP2015505309A (ja) 2015-02-19
JP2015505309A5 true JP2015505309A5 (cg-RX-API-DMAC7.html) 2015-04-02

Family

ID=45529152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549542A Pending JP2015505309A (ja) 2011-12-29 2011-12-29 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ

Country Status (7)

Country Link
US (1) US10596246B2 (cg-RX-API-DMAC7.html)
EP (1) EP2797624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015505309A (cg-RX-API-DMAC7.html)
AU (1) AU2011384634A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014016223A8 (cg-RX-API-DMAC7.html)
CA (1) CA2862247A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013098589A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
HK1253310A1 (zh) 2015-06-02 2019-06-14 Intravacc B.V. 革兰氏阴性菌外膜囊泡抗原表面展示
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2171418T3 (es) 1992-08-31 2002-09-16 Baxter Healthcare Sa Vacunas contra neisseria meningitidis del grupo c.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU7701098A (en) 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
EP1123403A1 (en) 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. 保存されたナイセリア抗原
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
BR0015961A (pt) 1999-11-29 2003-06-10 Chiron Spa Antìgeno de neisseria de 85kda
JP2003523208A (ja) 2000-01-25 2003-08-05 ザ ユニバーシティ オブ クイーンズランド 髄膜炎菌表面抗原NhhAの保存領域を含むタンパク質
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1476197B1 (en) 2002-02-22 2009-01-07 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
MXPA05011110A (es) 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP4005595A1 (en) 2005-04-08 2022-06-01 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PT3466982T (pt) 2005-04-08 2020-07-24 Wyeth Llc Separação de contaminantes do polissacárido de streptococcus pneumoniae por manipulação do ph
DK2283857T3 (da) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP5260531B2 (ja) 2006-10-10 2013-08-14 ワイス・エルエルシー 肺炎連鎖球菌3型多糖体の精製
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
HRP20201076T1 (hr) * 2009-03-24 2020-10-30 Glaxosmithkline Biologicals Sa Adjuvantni vezujući protein meningokokalnog faktora h
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
FI2608805T4 (fi) 2010-08-23 2025-08-07 Wyeth Llc NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens

Similar Documents

Publication Publication Date Title
JP2015505309A5 (cg-RX-API-DMAC7.html)
JP2014503172A5 (cg-RX-API-DMAC7.html)
JP2013502918A5 (cg-RX-API-DMAC7.html)
JP2012501959A5 (cg-RX-API-DMAC7.html)
JP2013520487A5 (cg-RX-API-DMAC7.html)
RU2012149618A (ru) Менингококковые полипептиды fhbp
CA2438080A1 (en) Gonococcal proteins and nucleic acids
JP2014500724A5 (cg-RX-API-DMAC7.html)
CN104844712B (zh) 肺炎链球菌蛋白抗原及其制备方法和应用
RU2007139915A (ru) Haemophilus influenzae типа в
BRPI0721003B8 (pt) composições e uso
RU2005119640A (ru) Множественные варианты менингококкового белка nmbi1870
JP2016040284A5 (cg-RX-API-DMAC7.html)
CN102711794A (zh) 用于疫苗和诊断学的Dps融合蛋白
JP2014507146A5 (cg-RX-API-DMAC7.html)
JP2015500827A5 (cg-RX-API-DMAC7.html)
JP2010508276A5 (cg-RX-API-DMAC7.html)
JP2012521404A5 (cg-RX-API-DMAC7.html)
JP2013504556A5 (cg-RX-API-DMAC7.html)
JP2012524099A5 (cg-RX-API-DMAC7.html)
JP2014502961A5 (cg-RX-API-DMAC7.html)
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
JP2015529677A5 (cg-RX-API-DMAC7.html)
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
Leng et al. Recombinant bacterial lipoproteins as vaccine candidates